GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa

Glaukos Corporation (GKOS) recently announced that the second Phase 3 confirmatory pivotal trial for Epioxa, the company's next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, successfully met the study's pre-specified primary efficacy endpoint. The results demonstrated a clinically relevant and statistically significant improvement in maximum corneal curvature (Kmax) at 12 months from baseline between the Epioxa treated arm and the sham/placebo-controlled arm. Kmax is a FDA ...